Green Alpha Advisors LLC Grows Position in Twist Bioscience Co. (NASDAQ:TWST)

Green Alpha Advisors LLC raised its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 31.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,708 shares of the company’s stock after acquiring an additional 4,944 shares during the period. Green Alpha Advisors LLC’s holdings in Twist Bioscience were worth $424,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of TWST. State Street Corp increased its position in shares of Twist Bioscience by 53.9% during the 2nd quarter. State Street Corp now owns 3,816,188 shares of the company’s stock valued at $133,414,000 after purchasing an additional 1,335,779 shares during the last quarter. BlackRock Inc. grew its position in Twist Bioscience by 13.2% during the 1st quarter. BlackRock Inc. now owns 6,213,441 shares of the company’s stock worth $93,699,000 after acquiring an additional 725,733 shares during the last quarter. JPMorgan Chase & Co. grew its position in Twist Bioscience by 19.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,895,151 shares of the company’s stock worth $92,743,000 after acquiring an additional 626,497 shares during the last quarter. Avidity Partners Management LP bought a new position in Twist Bioscience during the 4th quarter worth approximately $14,548,000. Finally, Nordea Investment Management AB bought a new position in Twist Bioscience during the 1st quarter worth approximately $7,472,000.

Analyst Ratings Changes

Several research firms recently issued reports on TWST. Barclays raised their price target on Twist Bioscience from $20.00 to $26.00 and gave the stock an “overweight” rating in a research report on Monday, August 7th. Robert W. Baird raised their price target on Twist Bioscience from $18.00 to $27.00 in a research report on Monday, August 7th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.67.

Twist Bioscience Trading Down 4.6 %

Shares of TWST stock opened at $21.99 on Friday. Twist Bioscience Co. has a fifty-two week low of $11.46 and a fifty-two week high of $41.87. The business’s 50 day moving average price is $22.50 and its 200-day moving average price is $18.08.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, August 4th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13. The firm had revenue of $63.80 million for the quarter, compared to analyst estimates of $60.62 million. Twist Bioscience had a negative return on equity of 29.09% and a negative net margin of 88.97%. The business’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period last year, the company earned ($1.08) EPS. On average, equities research analysts expect that Twist Bioscience Co. will post -3.73 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.